Company profile
Replimune Group, Inc.
NASDAQ:REPLBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NIVOLUMAB | phase2 | — | 221 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06581406 | phase2_3 | recruiting | 2024-12-17 | 2030-01-01 | Replimune, Inc. | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| NCT05733611 | phase2 | terminated | 2023-06-29 | 2025-08-18 | Replimune, Inc. | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC |
| NCT04050436 | phase2 | active_not_recruiting | 2019-10-08 | 2025-09-01 | Replimune, Inc. | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer |
| NCT03767348 | phase2 | active_not_recruiting | 2017-09-20 | 2028-06-01 | Replimune, Inc. | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) |
| NCT04336241 | phase1 | active_not_recruiting | 2019-10-17 | 2026-10-31 | Replimune, Inc. | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125827 | BLA | Replimune, Inc. | ||||
Loading… | ||||||